There is a cruel reality in crypto: the vast majority of projects only appear once in the public eye. When the hype is high, various KOLs write lengthy analyses overnight; once the hype fades, their names are no longer seen on social media timelines, as if they never existed. Injective is somewhat of a 'stubborn' participant: it's not at the center of discussions every day, but as soon as any hotspot related to derivatives or on-chain trading emerges, it can always be pulled back into the discussion.
This ability to 'repeatedly return to the spotlight' is essentially a form of narrative stickiness. Looking back over the past two years, you can probably recall several waves of scenes: the perpetual return of on-chain derivatives, the concentrated discussion on MEV fairness, the ups and downs of the Cosmos ecosystem, the performance competition among public chains, and the RWA concept being repeatedly mentioned... Each round of core topics actually intersects with Injective's own positioning. This leads to one result: it doesn't need to rely on 'forcefully creating hotspots' to enhance its presence; rather, the track itself is driving it to be repeatedly brought up. This rhythm is quite healthy for a public chain project.
You will neither be rushed to unsustainable heights due to short-term emotional surges, nor will you be completely forgotten during a prolonged calm period. The price of the INJ token, in the context of overall market fluctuations, has also managed to follow a trajectory of 'occasional surges and drops, yet not disappearing from the rankings' — this is already a considerable survival capability in the highly competitive crypto circle. Of course, from the perspective of ordinary participants, the biggest concern will always be: is it already 'too expensive' to look at it now? No one can provide a standard answer to this question; any reference to 'cheap' or 'expensive' carries the filter of one’s own holding structure.
A more realistic approach might be to ask yourself in reverse: if over the next year or two, the line of 'on-chain derivatives + professional trading infrastructure' continues to advance, is there a target with more authority and more solid data than Injective? If there is, then study that; if not, at least it indicates that it is still an inescapable sample in this track.
My personal feeling is that in such a market with extremely high information noise, those projects that can be repeatedly recalled and re-researched tend to survive longer. Injective currently appears to be this type of 'the more you look, the more familiar it becomes' — not necessarily the most dazzling, but very hard to completely ignore.@Injective #Injective $INJ
